Quick Takeaways
- Mark N. Tompkins filed SCHEDULE 13G/A for Lomond Therapeutics Holdings, Inc. Common Stock, par value $0.0001 per share.
- Disclosed ownership: 4%.
- Date of event: 31 Dec 2024.
Mark N. Tompkins - 31 Dec 2024 SCHEDULE 13G/A Report for Lomond Therapeutics Holdings, Inc. Common Stock, par value $0.0001 per share
- Filing Manager
- Mark N. Tompkins
- Reporting Manager
- Mark N. Tompkins
- Shares outstanding
- 29,687,500 shares
- Disclosed Ownership
- 1,187,500 shares
- Ownership
- 4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:00:06 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Mark N. Tompkins disclosed 4% ownership in Lomond Therapeutics Holdings, Inc. Common Stock, par value $0.0001 per share on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Mark N. Tompkins | 4% | 1,187,500 | 1,187,500 | 0 | /s/ Mark N. Tompkins | Mark N. Tompkins |